Taysha ends work on gene therapy after Astellas walks away, FDA requests randomized trial

Astellas has turned down the chance to option an asset from Taysha Gene Therapies. And, with Taysha identifying study design feasibility challenges after talking with the FDA, the biotech has stopped internal development of the candidate and added it to a large pile of dropped and deprioritized programs.